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Androgen receptor knockoutBone marrow derived mesenchymal stem cells (BM-MSCs) have been widely applied in several clinical trials
of diseases, such as myocardial infarction, liver cirrhosis, neurodegenerative disease, and osteogenesis
imperfecta. Although most studies demonstrated that transplantation of BM-MSCs did exert a temporary
relief and short-term therapeutic effects, eventually all symptoms recur, therefore it is essential to improve
the therapeutic efﬁcacy of transplantation by either elevating the self-renewal of BM-MSCs or enhancing
their survival rate. Herein we demonstrated that the BM-MSCs and adipocyte derived mesenchymal stem
cells (ADSCs) isolated from the androgen receptor (AR) knockout mice have higher self-renewal ability
than those obtained from the wild-type mice. Knockdown of AR in MSC cell lines exhibited similar results.
Mechanistic dissection studies showed that the depletion of AR resulted in activation of Erk and Akt signaling
pathways through epidermal growth factor receptor (EGFR) activation or pathway to mediate higher self-
renewal of BM-MSCs. Targeting AR signals using ASC-J9® (an AR degradation enhancer), hydroxyﬂutamide
(antagonist of AR), and AR-siRNA all led to enhanced self-renewal of MSCs, suggesting the future possibility of
using these anti-AR agents in therapeutic approaches.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Bone marrow derived mesenchymal stem cells (BM-MSCs) are
heterogeneous, pluripotent, and able to differentiate into multi-
lineage mesodermal cell types, including osteocytes, adipocytes,
chondrocytes, and muscular cells. These pluripotent stem cells are
thought to act as a reservoir for tissue regeneration after a normal cel-
lular turnover or in some damaged tissues. Due to this characteristic
of BM-MSCs, they have been widely applied in several clinical trials
to treat diseases, such as myocardial infarction, liver cirrhosis, sepsis,
and osteogenesis imperfecta [1–6]. Although scientists have shown
exciting improvement effects at the beginning of the BM-MSCs trans-
plantation, eventually the symptoms recur [7]. Also, it has been shown
that only low numbers of BM-MSCs can ﬁnally migrate to the damaged
organs becausemicroischemia causes the apoptosis of BM-MSCs during
translocation [8]. Therefore, to improve the self-renewal and cell sur-
vival of BM-MSCs after transplantation is urgent and essential for the
successful application of BM-MSCs in clinical use.r Cancer Research, Department
ilmot Cancer Center, Universi-
O. Lee),
l rights reserved.The antagonist of androgen, nilutamide, has been reported to in-
crease the proliferation of embryonic stem cells (ESCs) (Chang et
al.), indicating that androgen/androgen receptor (AR) might suppress
the self-renewal of stem cells. However, the effects of androgens
and AR on self-renewal of BM-MSCs have not been tested comprehen-
sively. In addition, the gender differences in the function of activated
BM-MSCs have also been suggested. Activated BM-MSCs are mainly
responsible for the reactions to stress challenges including hypoxia
and oxidative stress. Female BM-MSCs secrete more cytokines against
stress challenges than male BM-MSCs [9,10]. To utilize BM-MSCs
transplantation in treating diseases, it is important to clarify how AR
regulates functions of BM-MSCs. We therefore investigated AR effects
on the self-renewal, proliferation, and differentiation of the BM-MSCs.
The self-renewal of BM-MSCs is regulated by cellular intrinsic and
extrinsic signaling. Extrinsic factors, including ﬁbroblast growth factor
(FGF), insulin-like growth factor (IGF), epidermal growth factor (EGF),
hepatocyte growth factor (HGF), and vascular endothelial growth fac-
tor (VEGF), have been shown to affect stem cell behaviors [11–13].
The effects of HGF and VEGF have been tested in the transplantation
of BM-MSCs for the preclinical myocardial infarction mouse model.
The overexpression of HGF and VEGF signiﬁcantly enhanced the re-
covery of myocardial infarction [14], suggesting that growth factors
induced better self-renewal of mesenchymal stem cells allowing bet-
ter therapy in vivo. Other cellular intrinsic signals, such as p-Erk1/2,
phosphorylated signal transducer and activator of transcription 3
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liferation, and differentiation in different kinds of stem cells [14–18].
However, there have been no reports discussing how AR inﬂuences
those signaling pathways to affect the self-renewal of BM-MSCs.
In this study, we isolated BM-MSCs and adipocyte derived mesen-
chymal stem cells (ADSCs) from the AR knockout (ARKO) male mice
and wild type (WT) male littermates [19], and clearly demonstrated
that depletion of AR enhanced the self-renewal of BM-MSCs and
ADSCs. The enhanced self-renewal was shown by colony forming
unit ﬁbroblast (CFU-f) assays and other proliferation indices, because
the CFU-f assay could be used to quantify the self-renewal potential of
BM-MSCs [20,21]. During our mechanism studies, we identiﬁed that
AR plays a negative role in the self-renewal of BM-MSCs through
suppression of Erk1/2 and Akt signaling via modulation of EGFR
molecule. Finally, we demonstrated that the currently available com-
pounds, ASC-J9® (an AR degradation enhancer) [22–24], AR-siRNA
[25], and hydroxyﬂutamide (HF) all could promote self-renewal of
the WT BM-MSCs, suggesting that depletion of AR in BM-MSCs can
enhance self-renewal of BM-MSCs.
2. Results
2.1. BM-MSCs and ADSCs express AR
Primary ADSCs and BM-MSCs were isolated from 8 week old male
mice. As shown in supplemental Table 1, the ﬂow cytometric analysis
results conﬁrmed their identity by exhibiting marker proﬁles consis-
tent with the previous studies [11,26]. The multi-lineage differentia-
tion capacities were also characterized in the isolated ADSCs and
BM-MSCs. The results exhibited that ADSCs were able to differentiate
into osteoblasts and adipocytes (identiﬁed by Alizarin Red and Oil
Red O staining, respectively in Fig. 1A). The adipogenesis markers,
AP2 (adipocyte fatty acid binding protein 4), LPL (lipoprotein lipase),
and PPARγ (peroxisome proliferator-activated receptor gamma), were
increased in differentiated ADSCs upon adipogenesis induction when
compared with vehicle control (Fig. 1C). The osteogenesis markers, BSP
(bone sialoprotein), Col1 (collagen 1), and OPN (osteopontin), were
elevated in the differentiated osteoblasts derived from ADSCs when
induced with osteogenic media (Fig. 1D). Similarly, the BM-MSCs also
showed multi-lineage differentiation capabilities (Fig. 1E, G, and H).
When we investigated AR levels in BM-MSCs and ADSCs, we found low
levels of AR expressions (Fig. 1B and F).
2.2. Depletion of AR enhances self-renewal of BM-MSCs and ADSCs
In order to investigate whether AR affects self-renewal of BM-MSCs
and ADSCs, we exploited the ARKO transgenic mice for studies. The
BM-MSCs and ADSCs were isolated from the ARKO male mice and their
WT male littermates. To conﬁrm whether AR is functional in wild type
(WT) MSCs, the MMTV luciferase assay was performed. We found that
AR in WT MSCs showed 2.5 times higher transactivation ability in tran-
scribing MMTV luciferase when compared with the basal levels in ARKO
MSCs (supplemental Fig. 1). After validating thatWTMSC AR is function-
al, the CFU-f assay [20,21]was performed to test their self-renewal ability.
The BM-MSCs and theADSCs isolated from theARKOmalemice exhibited
higher CFU-f numbers than those of WTmale littermates (Fig. 2A and B),
suggesting higher self-renewal in ARKO MSCs (AR expressions in
BM-MSCs and ADSCs were shown in Fig. 2A and B, respectively to
demonstrate AR knockout efﬁciency). Similar results were observed in
sub-cultured BM-MSCs (P0—1 passage and P2—3 passages, Fig. 2C and
D), indicating that the increased self-renewal of MSCs is not a transient
phenomenon that only occurred in freshly prepared MSCs.
To conﬁrm the differentiation ability of WT and ARKO BM-MSCs,
osteogenic and adipogenic media were used to induce the BM-MSCs
differentiation into adipocytes and osteoblasts, respectively. The re-
sults showed that the initiation timings of calcium deposition werearound 21 days in both WT and ARKO MSCs and DMP1 expressions
were robustly increased in WT and ARKO MSCs at day 21 (supple-
mental Fig. 2), implying that AR did not inﬂuence the initiation timing
of the osteocyte formation process (Fig. 2E). This result suggests that
higher numbers of CFU-osteoblast (CFU-O) and CFU-alkaline phos-
phatase (CFU-ALP) observed in ARKO BM-MSCs were due to the dif-
ferential self-renewal potential between WT and ARKO BM-MSCs,
but not the altered differentiation process (supplemental Fig. 3A
and B). We also found higher numbers of CFU-adipocytes in ARKO
MSCs than WT MSCs (supplemental Fig. 3C). The ﬂow cytometric
analysis results also revealed that WT and ARKO MSCs were similar
in the stem cell surface marker proﬁles, while the original total
bone marrow mononuclear cells showed no difference between WT
and ARKO male mice (data not shown).
The established MSC cell lines, C3H10T1/2 (embryo derived MSC
line) and D1 (BM-MSC line), were used to conﬁrm the above ﬁndings.
The AR overexpressed and knocked down stable clones of C3H10T1/2
and D1 cells were selected based on Western blot and qRT-PCR data
(Fig. 3A and D). To evaluate whether AR can affect self-renewal of
established cell lines, their self-renewal potentials were examined
by MTT assay. Since all of them were stem cells, cell growth assays
could be used to quantify their cell numbers to determine their
self-renewal. The results showed that knockdown of AR in C3H10T1/2
cells promoted their cell growth (Fig. 3B), whereas overexpression of
AR repressed their growth (Fig. 3C). Similar results were observed in
D1 stable clones (Fig. 3E and F).
2.3. AR inhibits proliferation of BM-MSCs and ADSCs, but has little effect
on apoptosis
Since the MTT assay is used to measure viable cells, we speculated
that the growth inhibition results might be from the combined effects
of proliferation and apoptosis differences. To answer whether deple-
tion of AR promotes stem cell proliferation or inhibits stem cell apop-
totic death, several proliferation/apoptosis assays were performed.
We found ARKO BM-MSCs show higher positive Ki67 staining
(Fig. 4A) and BrdU labeling (Fig. 4B) than WT BM-MSCs. Similar re-
sults were obtained in ADSCs showing higher numbers of Ki67 posi-
tive cells in ARKO ADSCs than in WT cells (Fig. 4C). MTT assay
results showed the promoted growth in AR knocked out ADSCs
(Fig. 4D). Higher expressions of proliferating cell nuclear antigen
(PCNA) were detected in ARKO ADSCs than in WT ADSCs (Fig. 4E).
In contrast, no signiﬁcant difference in apoptotic death was observed
between WT and ARKO BM-MSCs (Fig. 4F and G), indicating that the
depletion of AR caused elevated self-renewal in BM-MSCs and ADSCs
and is due to proliferation effects rather than apoptotic death.
2.4. AR acts as a suppressor in the self-renewal potential of stem cells
through inhibiting Akt and Erk1/2 signaling via EGFR
To dissect the potential mechanism by which targeting AR en-
hances self-renewal of BM-MSCs, p16 (Ink4a) and p19 (Arf) levels
in ARKO and WT BM-MSCs were examined, since they were shown
to play important roles in regulating stem cell self-renewal [27,28].
We found that targeting AR either in primary BM-MSCs or in
C3H10T1/2 (mouse mesenchymal stem cell lines) did not affect the
expressions of p16 and p19 (Fig. 5A–I). On the other hand, other key
regulators, such as Erk1/2, Akt, and STAT3,were reported to play impor-
tant roles in maintaining the stemness and promoting the self-renewal
of stem cells [14–18]. Our results showed that higher p-Akt and p-Erk1/
2 levels, but not higher p-STAT3 expression, were observed in ARKO
BM-MSCs andADSCs as compared toWT controls (Fig. 5J and K). Similar
results were obtained in C3H10T1/2 and D1 cells (Fig. 5L and M). The
reporter assay of Elk1, one of the downstream signaling molecules of
p-Erk1/2, was performed to validate Erk1/2 signaling transduction
1224 C.-K. Huang et al. / Biochimica et Biophysica Acta 1833 (2013) 1222–1234
Fig. 2. AR suppresses self-renewal of BM-MSCs and ADSCs. (A) CFU-f tests representing self-renewal abilities of BM-MSCs and ADSCs were performed with BM-MSCs of WT and
ARKO mice. BM-MSCs isolated from 8 week old WT and ARKO mice were seeded onto 6-well plates and the colonies formed were stained with 1% methyl blue. Colonies with
more than 20 cells were counted as positive (n=9). (B) ADSCs isolated from 8 week old WT and ARKO mice were seeded onto the 6-well culture plates and CFU-f assay was
performed. (C-D) CFU-f tests were performed with (C) BM-MSCs of passage 0 and (D) BM-MSCs of passage 2. (E) Alizarin Red staining was performed to determine differentiation
of BM-MSCs into osteoblasts. Presented CFU-O numbers were reﬂective of colony forming ability. (F) Flow cytometry results in CD44, CD29, and CD34 were shown inWT and ARKO
BM-MSCs. *p-valueb0.05, **p-valueb0.01, ***p-value b0.001 when compared with controls.
Fig. 1. Identiﬁcation of stem cell characteristics. (A) Representative images of morphology, adipogenesis, and osteogenesis of isolated primary ADSCs. Adipogenesis was conﬁrmed
with oil droplets, vacuole like structure, and Oil Red O staining (red color). Osteogenesis was conﬁrmed with Alizarin Red staining (red color). (B) Western blot results of
AR and α-tubulin in ADSCs and LNCaP, positive control for AR. (C-D) qRT-PCR was used to quantify the marker expressions of (C) AP2, LPL, and PPARγ for adipogenesis and
(D) BSP, Col1, and OPN for osteogenesis in ADSCs. Ctrl is vehicle control without differentiation induction. (E) Representative images of morphology, adipogenesis, and osteogenesis
for BM-MSCs. (F) Western blot results of AR and α-tubulin in BM-MSCs and LNCaP. (G) Adipogenesis and (H) osteogenesis marker expressions in BM-MSCs. n=5, *p-valueb0.05,
**p-valueb0.01 when compared with controls. Student t test was used to perform statistical analysis.
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Fig. 3. AR is critical in growth of stem cells. (A) Western blot analysis of AR expressions in AR overexpressing and knocked down C3H10T1/2 clone cells. α-Tubulin served as internal
control. Numbers represent different clones. MTT assays were performed in C3H10T1/2 cell lines which were manipulated (B) either with AR knocked down (siAR5, siAR7) and
scramble control or (C) with AR overexpression (AR1, AR5) and vector control. Cell growth at days 0, 1, 2, and 3 was analyzed. (D) qRT-PCR analysis result of AR mRNA expressions
in virus infected D1 cells. (E, F) MTT assays were also performed with D1 cell line, (E) with AR knocked down clone and scramble control cells, and (F) with AR overexpressing clone
and vector control cells. Cell growth at days 0, 1, 2, and 3 was analyzed. *p-valueb0.05, when compared to the control.
1226 C.-K. Huang et al. / Biochimica et Biophysica Acta 1833 (2013) 1222–1234and the result showed that overexpression of AR in C3H10T1/2
suppressed the Elk1 transactivation (Fig. 5N).
This signaling was further conﬁrmed via blocking Erk1/2 and
Akt pathways with the inhibitors, PD98059 (MEK1 inhibitor) and
LY294002 (inhibitor of phosphatidylinositol 3 kinase). Blocking
p-Erk1/2 and p-Akt with inhibitors completely reversed the ARKO
enhanced self-renewal of BM-MSCs (Fig. 5O and P). The PCNA expres-
sions were determined to further validate the observation and we
found that the treatments with p-Erk1/2 and p-Akt inhibitors partial-
ly masked the PCNA difference between WT and ARKO BM-MSCs
(Fig. 5Q). We therefore concluded that knockout of AR promotes
the self-renewal potential of MSCs through activating Erk1/2 and
Akt signaling.
EGFR, HGF, VEGFs, FGFs, and IGF are upstream of Erk1/2 and Akt
and reported to modulate the self-renewal of stem cells [12,13,29],
and AR has been suggested to affect those molecules [30–33]. We
therefore investigated the expressions of these molecules to deter-
mine which molecule is upstream of Erk1/2 and Akt signaling and
critical in ARKO mediated self-renewal. The results revealed that
the expressions of HGF, VEGF-B, and VEGF-C mRNAs were not signif-
icantly altered in WT and ARKO BM-MSCs (Fig. 6A, B, and C). mRNA
levels of HGF, VEGF-B, VEGF-C, FGF7, and FGF10 in CH3H10T1/2 cell
line were found to be not signiﬁcantly different after manipulating
AR expression (Fig. 6D–H). We then further tested AR effects on
EGFR expression, since AR and EGFR interaction has been demon-
strated in prostate cancers [30,31]. We found both short-term and
long-term androgen treatments signiﬁcantly promoted AR to translo-
cate into the nucleus (supplemental Fig. 4). In addition, as shown in
Fig. 6I and J, knockdown of AR in C3H10T1/2 and D1 cells increased
the expressions of EGFR and p-EGFR, whereas overexpression of AR
in C3H10T1/2 and D1 cells inhibited the expressions, demonstrating
the negative correlation of EGFR level and AR expression. Activation
of Erk signaling along with p-EGFR level was also negatively corre-
lated with the AR level (Fig. 6K). The ARKO BM-MSCs exhibitedsigniﬁcantly higher expressions of EGFR mRNAs than WT BM-MSCs
(Fig. 6L). Overexpression of AR in C3H10T1/2 cells suppressed EGFR
mRNA expression (Fig. 6M).
To dissect the molecular mechanism by which AR regulates EGFR
expression, we constructed the pGL3-luciferase vector containing
EGFR promoter regions to test AR effects on EGFR transactivation. We
found that AR suppressed EGFR promoter activity in a dose dependent
manner, suggesting that ARmediated EGFR expression at the transcrip-
tional level (Fig. 6N and supplemental Fig. 5). To see whether AR medi-
ated EGFR expression is involved in ARKO enhanced self-renewal of
BM-MSCs, we used EGFR inhibitor (AG1478) to treat ARKO BM-MSCs
and found that EGFR inhibitor treatment abolished the ARKO enhanced
self-renewal of BM-MSCs (Fig. 6O). Conversely, administration of epi-
dermal growth factor (EGF) in WT BM-MSCs increased CFU-f number
and enhanced PCNA expressions (Fig. 6P and Q), suggesting that EGF
could promote the self-renewal of BM-MSCs even in the presence of
AR, which suppresses EGFR expression. The p-EGFR and p-Erk1/2 were
examined to see whether EGFR signaling was activated upon EGF addi-
tion and we found that addition of EGF activated EGFR and Erk1/2
signaling (Fig. 6R). In summary, the antagonistic effects of AR on the
self-renewal of BM-MSCs are considered to be through the EGFR, be-
cause activation of EGFR signaling with EGF still can overcome the AR
effects in suppressing the self-renewal potential of BM-MSCs.
Taken together, the results from Figs. 5 and 6 suggested that AR
plays a suppressive role in the self-renewal of MSCs through suppres-
sion of the EGFR expression, which in turn, leads to inactivation of Akt
and Erk signaling. The brief signaling cartoon is presented in Fig. 7.
2.5. Treatments with anti-androgen/anti-AR drugs promote the
self-renewal of BM-MSCs from WT mice but not from ARKO mice
The three currently available methods, HF, ASC-J9®, and lentiviral
siRNA, for targeting AR were then applied to determine if suppression
of AR in BM-MSCs using these methods yields the similar effects as
Fig. 4. Depletion of AR in BM-MSCs and ADSCs stimulates their proliferation. (A) IHC staining results of Ki67. BM-MSCs isolated from 8 week old WT and ARKOmice were seeded on
culture plates. Percentage of positive staining was expressed as positive Ki67 signals/total nuclear signals, n=6. (B) BrdU labeling experiment result. Percentage of positive staining
was calculated as positive BrdU signals/total nuclear signals, n=7. (C) IHC staining result of Ki67 in ADSCs that were isolated from 8 week old WT and ARKO mice, n=4. (D) MTT
assay result of ADSCs of WT and ARKO mice. Percentage of growth was normalized to the highest value (set as 100%). (E) Western blot analysis showing expression of PCNA in
ADSCs obtained from the WT (WT1 and WT2) and the ARKO (ARKO1 and ARKO2) mice. α-Tubulin was used as control. (F) TUNEL staining was performed according the
manufacturer's instructions to examine apoptotic death of BM-MSCs of WT and ARKO mice. Positive control provided in the TUNEL assay kit was applied. Green ﬂuorescence signal
represents the positive apoptosis signal. (G) Quantitation of TUNEL staining results. **p-valueb0.01, when compared to controls.
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HF increased the self-renewal of WT BM-MSCs (Fig. 8A), but not
ARKO BM-MSCs (Fig. 8B). The HF effect on the activation of EGFRsignaling was examined byWestern blotting and the results exhibited
that the expressions of p-EGFR, EGFR and p-Erk were enhanced upon
HF treatment (Fig. 8C and D). The similar effects were observed in the
Fig. 5. Erk1/2 and Akt signals are critical in AR knockout enhanced self-renewal of BM-MSCs. (A)–(I), qPCR analysis results of AR, p16 and p19 in C3H10T1/2 and primary
BM-MSCs after manipulation of AR either with overexpression or knockdown. (A)–(F) with C3H10T1/2 cell line and (G)–(I) with primary BM-MSCs. BM-MSCs were isolated
from 8 week old WT and ARKO mice. (J, K) Western blot analysis results of STAT3, p-STAT3, Erk1/2, p-Erk1/2, Akt, and p-Akt in primary (J) BM-MSCs and (K) ADSCs. (L, M),
Western blot analysis results of p-Erk1/2, Erk1/2, p-Akt, Akt, p-MEK, and MEK in (L) C3H10T1/2 and (M) D1 cells after transfecting with either AR-siRNA (with scramble control)
or AR (with vector control). (N) Elk transactivation assay was performed by co-transfection of AR, GAL4-Elk, and pG5-luciferase plasmids into C3H10T1/2 cells. BM-MSCs were
isolated from WT and ARKO mice, seeded on 6-well plates at a density of 2×106/well, treated with (O) 10 μM PD98059 and (P) 10 μM LY294002, and CFU-f numbers were
examined. PD98059 and LY294002 were administrated to the culture media every 2 days until completion of experiments. **p-valueb0.01, when compared to the control.
Fig. 6. The activation of Akt and Erk signaling in AR knocked out BM-MSCs is through EGF/EGFR. (A)–(H) qPCR analysis results of HGF, VEGF-B, VEGF-C, KGF, and FGF10 in primary
BM-MSCs and C3H10T1/2 cell line. BM-MSCs were isolated fromWT and ARKOmice at ages of 8–12 weeks. (A–C) are the results obtained with primary BM-MSCs isolated fromWT
and ARKOmice and (D–H) represent the results with C3H10T1/2 cell line after manipulation of AR expression. (I–K)Western blot results in expression levels of EGFR, and p-EGFR in
(I) C3H10T1/2, (J) D1, (K) HEK-293 cell lines after manipulation of AR expressions. (L, M) qPCR analysis results of EGFR in (L) primary BM-MSCs of WT and ARKO mice and (M)
C3H10T1/2 cell line after AR overexpression. (N) EGFR promoter assay was performed in HEK-293T cells. From lanes 1 to 4, AR was increasingly added to the experimental set
as drawn in the image. (O) CFU-f test result of BM-MSCs of WT and ARKO mice after treatment with EGFR inhibitor (AG1478, 0.5 μM). (P) 20 ng/ml EGF was used to treat WT
BM-MSCs to see EGF effect on the CFU-f and (Q) p-EGFR, EGFR, pErk1/2, and pErk1/2 were measured using Western blot. **p-valueb0.01, when compared with control.
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Fig. 7. Illustration of AR mediated EGFR signaling in BM-MSC self-renewal. Transcriptional factors (TFs).
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fects of ASC-J9® on AR degradation have been reported previously
[22–24]. Our CFU-f assay results showed that ASC-J9® enhanced
the self-renewal of BM-MSCs in WT male mice (Fig. 8E), but had
no effects on ARKO BM-MSCs (Fig. 8F). Furthermore, we examined
the effect of infection with the lentivirus packed with AR-siRNA on
the self-renewal of the BM-MSCs, and found that the lentiviral infec-
tion signiﬁcantly enhanced the self-renewal of the BM-MSCs
(Fig. 8G). Finally, we tested the effects of those compounds in the
BM-MSCs self-renewal with CFU-f assay in the presence of exoge-
nous ligand treatment and obtained similar results (supplemental
Fig. 6).
Collectively, the three current available approaches of targeting
AR all resulted in the consistent conclusion that targeting AR in
BM-MSCs increases their self-renewal.
3. Discussion
BM-MSCs transplantation has been widely applied in the clinical
trials to treat diseases such as myocardial infarction, osteogenesis
imperfecta, and liver cirrhosis. However, most of these clinical trials
using BM-MSC transplantation to treat patients exhibit short-term
improvement followed with recurring symptoms. The possible mech-
anism of this recurrence might be due to low numbers of BM-MSCs
that are reaching the target organs [34–37]. Meanwhile, gender dif-
ferences have been shown in the function of activated BM-MSCs
which are responsible for the stress challenge, such as oxidative stress
[9,10]. Therefore, our studies attempt to clarify whether the role of AR
is essential in order to better utilize BM-MSCs in the clinic. The results
of this study are the ﬁrst demonstration showing depletion of AR en-
hances the self-renewal potential of BM-MSCs via elevated EGFR
without inﬂuencing differentiation and apoptosis.
The female sexual hormone and its receptors, estrogen receptor α
and β, are other crucial determinant mechanisms in gender dimor-
phism. It has been shown that estrogens promote proliferation of
embryonic stem cells via promoting the MAPK cascade to affect the
important cell cycle components, cyclins D1 and E [38]. The effects
of estrogen on BM-MSCs have also been suggested in in vitro apopto-
sis and in vivomyocardial recovery. Estrogen inhibits the apoptosis of
BM-MSCs through the Bcl-xL and Bcl2. Estrogen treatment improves
the therapeutic effect of BM-MSCs in the myocardial recovery after
ischemia [39,40]. In the neural stem cells, estrogen plays a positive
role in inducing the neuronal phenotype from embryonic stem cells
and stimulating the proliferation of embryonic neural stem cells
[41,42]. However, estrogens seem to suppress the hematopoieticstem cell population and differentiation. It has been shown that male
infants have a higher median CD34+ concentration in their cord
blood than female infants. Also, estrogens negatively inﬂuence the
production of B cells by changing the differentiation, proliferation,
and survival of B cell precursors.
For the androgenic effects on the stem cell behaviors, the previous
studies mainly used androgen treatments to explore the inﬂuence
of male sexual hormones in stem cells. Chang et al. demonstrated
that anti-androgens, such as nilutamide, could stimulate the growth
of ESCs, but testosterone has no effects on the growth of ESCs [16].
For the osteoprogenitors, it has also been shown that testosterone
has no effects on BM-MSC differentiation into osteoblasts [43], but
AR deﬁciency inhibits osteogenic differentiation [44]. In addition,
high doses of androgen increased the cardiomyocyte differentiation
in ESCs [45]. However, AR effect has never been tested in the self-
renewal potential of BM-MSCs and it should be acknowledged that
the androgenic effects and the AR effects are not always the same,
such as androgen and AR inﬂuence the osteogenic differentiation
of BM-MSCs differentially. We are the ﬁrst to identify that AR plays
a suppressive role in the self-renewal of BM-MSCs with clear demon-
strations that depletion of AR stimulates the self-renewal potential
of BM-MSCs through elevating EGFR expression. The increased
EGFR activates the signaling pathways of Akt and Erk. The inhibitor
studies using PD98059 (MEK1 inhibitor) and LY294002 (inhibitor
of phosphatidylinositol 3 kinase) indicated that blocking of these
two signaling pathways abolishes the AR knockout effects on the in-
creased self-renewal of BM-MSCs. Further studies using the p-EGFR
inhibitor to challenge ARKO BM-MSCs exhibited that the inhibitory
effects of AR on the self-renewal of BM-MSCs are through EGFR sig-
naling. Since those inhibitors might have side effects on other path-
ways, we therefore directly applied the EGF to the WT BM-MSCs to
see whether AR mediated BM-MSCs self-renewal is EGFR dependent.
Indeed, EGF activated EGFR signaling increased the self-renewal
potential of WT BM-MSCs that have intact AR. Based on these
data, it can be concluded that AR plays a suppressive role in the
self-renewal of BM-MSCs by inactivating Akt and Erk signaling via
down-regulating EGFR.
With our clariﬁcation of the AR role in enhancing the self-renewal
of BM-MSCs, a question may arise as to whether the current available
compounds can be applied to target AR and result in increased
self-renewal potential of BM-MSCs. We have tested the effects of
three AR targeting approaches, ASC-J9® (AR degradation enhancer),
HF (antagonist of AR), and AR-siRNA on self-renewal of BM-MSCs.
All of them showed signiﬁcant enhancements in the self-renewal
potentials of BM-MSCs. The chemical castration method using anti-
Fig. 8. Blocking the androgen/AR signaling increased the self-renewal of BM-MSCs in WT mice, but not in ARKO mice. CFU-f test results of primary BM-MSCs of (A) WT and (B)
ARKO mice in the presence of EtOH (vehicle) or 1 μM HF. (C) p-EGFR and EGFR expressions in C3H10T1/2 upon HF treatment (left panel) and primary WT BM-MSCs treated
with ASC-J9® (right panel). (D) Western blot analysis results of pErk1/2 and Erk1/2 levels in C3H10T1/2 cells that were treated with vehicle or 1 μM HF. (E, F) CFU-f test results
of BM-MSCs that were treated with DMSO (vehicle) or 5 μM ASC-J9®. (G) CFU-f test results of WT BM-MSCs that were infected with lentivirus packed with either scramble or
AR-siRNA. **p-valueb0.01, ***p-value b0.001, when compared to the control.
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side-effects of restraining patient libido and fertility. On the other
hand, despite many recent successful improvements, whether the de-
livery of siRNAs is effective without any unexpected side effects is an-
other serious issue we currently face. However, the use of ASC-J9®,
which has been reported to degrade AR selectively in different cell
types without inﬂuencing mouse fertility, and has limited
side effects, could be an alternative choice. This drug has successfully
completed the Phase II clinical trials (http://www.androscience.com/
artman/publish/news/press-release030609.shtml).
In summary, we clearly demonstrated that; (i) the depletion of AR
enhances the self-renewal potentials of BM-MSCs and ADSCs, but does
not signiﬁcantly affect differentiation and apoptosis of BM-MSCs, and
(ii) we dissected the molecular mechanism by which knockout of
AR enhances the self-renewal of BM-MSCs through up-regulation of
EGFR. The elucidation of this study does not only indicate the suppres-
sive role of AR in self-renewal potential of BM-MSCs but also provides
evidence that degrading AR with the currently available compounds
can exert the similar effects. These novel ﬁndings imply a possibility
of targeting AR in BM-MSCs in clinical applications to improve the
efﬁciency of BM-MSC transplantation in treating various diseases,
such as liver cirrhosis, sepsis, autoimmune diseases, and myocardial
infarction.4. Materials and methods
4.1. Cells, animals and reagents
C3H10T1/2 and D1 cells were purchased from ATCC (Manassas,
VA) and the culture conditions were used as shown in the manual.
The BrdU labeling kit was purchased from ZYMED Invitrogen (Grand
Island NY). All animal studies followed the “Guide for the Care and
Use of Laboratory Animals” (National Institutes of Health publication).
The protocols were reviewed and approved by the University
Committee on Animal Resources of the University of Rochester. We
used Cre–Lox strategy to generate WT and ARKO mice. The ﬂoxed AR/
AR mice were established in our previous publication [19]. WT and
ARKO mice were established by mating ﬂoxed AR/AR female mice
with Actb Cre+/+ mice. The ﬂoxed AR/Y-Actb Cre+/− mice were used
as ARKO and AR/Y-ActbCre+/− were used as WT control. Oil Red O
and Alizarin Red were purchased from Sigma-Aldrich (St. Louis, MO).
4.2. Isolation of BM-MSCs
For the isolation of mouse BM-MSCs, we followed the protocol
described previously [46]. Brieﬂy, tibias and femurs were dissected
from adult mice 8–10 weeks old. After bones were cut, the marrows
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and resuspended in DMEM plus 15% FBS. After counting, about
2×106 mononucleated cells were plated on a 25 cm2 plastic ﬂask
in DMEM (Gibco), supplemented with 15% fetal bovine serum
(FBS), 2 mM L-glutamine, 100 U/ml penicillin, 100 mg/ml strepto-
mycin, and 10 mM HEPES. All of the cells were incubated at 37 °C
with 5% humidiﬁed CO2. After the ﬁrst 24 h, we removed the non-
adherent cells by replacing the medium every 3 or 4 days for about
3 weeks. When the cells grow to conﬂuence, they were harvested
with 0.25% trypsin and 1 mM EDTA (Hyclone) for 5 min at 37 °C,
re-plated on 25 cm2 plastic ﬂask, again cultured to next conﬂuence,
and harvested.
4.3. Isolation of ADSCs
ADSCs were isolated as described in Ning et al. [47]. Brieﬂy, subcu-
taneous adipose were removed with sterile forceps and scissors from
the inguinal region of male mice and then minced to small pieces.
Tissues were mixed with 3 volumes of phosphate buffer saline (PBS)
and then centrifuged at 1000 rpm for 5 min. Pellets were digested
with 0.075% collagenase (Sigma-Aldrich) for 1 h at 37 °C with shaking.
After digestion, the mixture was centrifuged at 1000 rpm for 5 min,
rinsed in 10 ml PBS and centrifuged at 1000 rpm for 5 min. 10 ml
DMEM with 10%FBS was added to the pellet, resuspended, and ﬁltered
through a 100 μm cell strainer (BD Bioscience). Cell pellets were put
into culture dish and then cultured for 3–5 days in 5% CO2 incubator
to get colonies of ADSCs.
4.4. EGFR promoter construction
EGFR promoter regions were ampliﬁed by using PCR with these
Primers Forward (−2396) 5′-GGGGTACCCCAAGCTCCCCTCCCA
CATATGT-3′, forward (831) 5′ GGGGTACCCCTGGGATCTGAAG
GACCCTTGGA-3′, and reverse 5′-CCGCTCGAGCGGCATCTCTGACCG
GGAGAGGTT-3′. After amplifying, we used KpnI and MluI to digest
the PCR product and pGL3 vector (Promega) at 37 °C overnight. We
then puriﬁed the digested fragment with Qiagen Gel puriﬁcation kit
following the instruction manual. The puriﬁed inserter and vector
were ligated together with T4 ligase at 16 °C overnight. The ligated
product was transformed with DH5α, applied on the LB agar plate
containing 100 μg/ml ampicillin, and incubated at 37 °C overnight.
The surviving and visible clones were picked up, examined, and se-
quenced to validate the EGFR promoter region.
4.5. CFU-f assay for self-renewal
Primary BM-MSCs were isolated from 8 week old mice and then
2×106 mononucleated cells were plated per well onto 6-well plates.
After culturing for 21 days, cells were ﬁxed with methanol and washed
with ddH2O. After washing, cells were stained with 1% methylene
blue for 15 min and cells were rinsed with ddH2O twice. We counted
colonies that have more than 20 cells as positive CFU-f.
4.6. Cell growth assays
4.6.1. MTT assay
MSCs were plated onto 24-well plates at a density of 5000 cells/
well. At each time point indicated, MTT solution was added to
cells to react for 30 min, medium removed, and DMSO added
to dissolve the MTT salt. The absorbance values were measured at
575 nm–650 nm.
4.6.2. Ki67 staining
Stem cells were seeded on the 4-well chamber slides and cultured to
conﬂuence and then ﬁxed with methanol. After ﬁxation, cells were
washed with PBS 3 times for 5 min each and then cells were blockedwith 1% fetal bovine serum for 1 h. Cells were washed with PBS 3
times, then incubated with anti-Ki67 (NCL-Ki67p, 1:1000) in 3% BSA
in PBS overnight at 4 °C, and then incubated with 1:200 diluted
biotinylated secondary antibody (Vector Laboratories) andABC solution
(Vector Laboratories). Cells were stained by AEC (DAKO, Carpentaria,
CA), followed by Mayor's hematoxylin counterstaining.
4.6.3. BrdU labeling
Stem cells were seeded on the 4-well chamber slides and cultured
to conﬂuence. BrdU labeling reagent (Invitrogen) was added to the
cultured cells at 1:100 dilution in the culture medium for 24 h. After
labeling, staining was performed according to the manual instruction
(Invitrogen, BrdU staining kit).
4.7. Western blot analysis assay
Antibodies used to detect the blot in this study were AR (Santa
Cruz, AR C19), Erk1/2 (Cell Signaling), p-Erk1/2 (Cell Signaling),
Akt (Cell Signaling), p-Akt (Cell Signaling), MEK (Cell Signaling),
p-MEK (Cell Signaling), EGFR (Santa Cruz, EGFR 1005), and p-EGFR
(Tyr 1173). Cell lysates were resolved with 10% sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), blotted with
antibodies mentioned above, and incubated with correlated secondary
antibodies conjugated with horseradish peroxidase. Proteins were
visualized according to the manual instructions (Pierce ECL Western
Blotting Substrate, Thermo Scientiﬁc). Tubulin served as loading control.
4.8. RNA extraction and real time quantitative PCR (qRT-PCR)
Total RNAs were extracted with Trizol (Invitrogen) according to
the manufacturer's instruction. Two μg mRNAs were used to reverse
transcribe to cDNAs using Superscript III (Invitrogen). Quantitative
qRT-PCR was performed using cDNA, speciﬁc gene primers, and
SYBR green master mix (Biorad) on an iCycler iQ Multi-color real-
time PCR machine (Biorad). qRT-PCR results were calculated as rela-
tive expressions to the control and normalized to the housekeeping
gene, GAPDH.
4.8.1. Apoptosis assay (TUNEL staining)
Apoptotic death of BM-MSCwas detected by using terminal deoxy-
ribonucleotide transferase (TdT)-mediated dUTP nick-end labeling
(TUNEL) detecting system as described previously [48].
4.9. Flow cytometry analysis of cell markers
BM-MSCs were detached with 0.2% EDTA and then washed with
1% FBS in PBS (ﬂow washing buffer). After washing, BM-MSCs
were stained with CD29 PE (eBioscience), CD34 FITC (eBioscience),
CD44 PE-Cy5 (eBioscience), CD45 FITC (eBioscience), CD106 FITC
(eBioscience), and CD117 PE (eBioscience) and washed again with
1% FBS in PBS. BM-MSCs were then resuspended in PBS and analyzed
by BD Accuri® C6 Flow Cytometry. Results were further analyzed
using FlowJo software according to the previous publication [49].
4.10. Adipogenesis and osteogenesis differentiations
For the adipogenesis differentiation, the isolated ADSCs and
BM-MSCs were plated on a 6-well plate. After the cells reached the
conﬂuent density, the adipogenesis media (DMEM containing 10%
FBS, 2 μg insulin, 10−8 M dexamethasone, and 2 μM rosiglitazone)
were added to induce adipogenesis differentiation [50]. After lipid
vacuole structures were observed, the Oil red O staining was used
to visualize the lipid vacuoles. For the osteogenic differentiation,
the conﬂuent ADSCs and BM-MSCs were treated with osteogenic
media (DMEM containing 10% FBS, 50 μg ascorbic acid, and 10 mM
1233C.-K. Huang et al. / Biochimica et Biophysica Acta 1833 (2013) 1222–1234β-glycerophosphate) to induce mineralization [51]. The mineralized
osteocytes were visualized using Alizarin Red staining.4.11. Lentivirus infection
HEK-293T cells were used to produce lentivirus by calcium-
phosphate transfection. 12 μg of lentivirus plasmid (pLVTHM-scramble,
pLVTHM-AR-siRNA, pWPI, pWPI-AR), 8 μg of pCMVdeltaR8.91 (con-
tains GAG, POL) 10 μg of pMD2.G (contains VSVg)were used to produce
virus in a 10-cm2 dish. Culture medium containing virus was collected
32 h after transfection and ﬁltrated through a 0.4 μm ﬁlter to remove
cell debris or cells. The collected virus were added to the target cells
in the presence of polybrene (2 μg/ml) to incubate for 24 h. Cells
were refreshed with culture medium and cultured for another 3 days
to let target protein express. Since the lentiviral vectors express green
ﬂuorescence protein, ﬂuorescence microscopy was used to monitor
the infection efﬁciency via checking the green ﬂuorescence signal.4.12. Transfection and stable clone selection
Cells were transfected with lipofectamine 2000 (Invitrogen)
according the manufacturer's instructions and then desired clones
were selected using appropriate antibiotics. For C3H10T1/2 cells,
600 μg/ml G-418 and 0.5 μg/ml puromycin were used to select stable
scramble, AR-siRNA, vector, and AR clones. For ESD3, 300 μg/ml
G-418 and 0.5 μg/ml puromycin were used to select stable clones.4.13. GAL4-Elk1 transactivation assay
For the Elk1 transactivation assay, C3H10T1/2 cells were seeded on
the 24-well plates one day before transfection [52]. pG5-luciferase,
GAL4-Elk1, and pCDNA3.1-ﬂag-AR were used to identify Elk1
transactivation. pRL-TK was used as internal control.4.14. Inhibitor studies of p-Erk1/2, p-Akt and p-EGFR
For the inhibitor study, primary BM-MSCs were isolated from
either WT or ARKO mice. After BM-MSCs were plated for culture
with, 10 μM PD98059 (Cell Signaling), 10 μM Lys94002 (Cell signal-
ing, or 0.5 μM AG1478 (Sigma), replenished every other day. After
21 days, CFU-f were visualized with 10% Giemsa staining or 1% meth-
yl blue staining.4.15. Statistical analysis
Values were expressed as mean±standard deviation (S.D.).
The Student's t test was used to calculate p values. P values were
two-sided, and considered statistically signiﬁcant when b0.05.Acknowledgements
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